Compare MBIO & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBIO | XAIR |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.4M |
| IPO Year | 2023 | 2015 |
| Metric | MBIO | XAIR |
|---|---|---|
| Price | $0.77 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 30.5K | ★ 330.7K |
| Earning Date | 05-13-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.99 | 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.53 | $0.15 |
| 52 Week High | $7.00 | $3.78 |
| Indicator | MBIO | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 35.12 |
| Support Level | $0.71 | $0.43 |
| Resistance Level | $1.00 | $0.82 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 82.92 | 19.85 |
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.